ArticleSexual medicine2022
Novel Marker for Premature Ejaculation: Serum Leptin Level.
Article in Sexual medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeptin, which was only discovered in humans in 1994, has recently been shown to have a possible link with premature ejaculation.
aimTo evaluate whether serum leptin levels differed between patients with premature ejaculation and healthy men, and to analyze the changes in leptin levels before and after treatment.
methodsSix studies assessing the relationship between leptin and premature ejaculation published up to October 2021 were identified from multiple databases (PubMed, Web of Science, Cochrane) and the data were analyzed by Stata software. OUTCOMES: Differences in leptin levels in premature ejaculation patients and healthy people, and changes of leptin levels in premature ejaculation population before and after treatment.
resultsAnalysis of studies assessing differences in leptin concentrations between patients with PE and healthy men showed that there was a statistically significant difference in leptin levels between PE patients and controls (WMD (95% CI) = 17.89 (8.64, 27.14), P < .001). On the other hand, the analysis of data from 3 studies describing serum leptin levels in PE patients before and after treatment with selective serotonin reuptake inhibitors (SSRIs) showed that there was a significant decrease with leptin levels in PE patients after treatment (WMD (95%CI) = 22.06 (17.21, 26.92), P < .001). CLINICAL IMPLICATIONS: It is possible that leptin can be used as a new marker for premature ejaculation. STRENGTH & LIMITATIONS: The strength of this study is that it is the first meta- analysis to assess the differences of serum leptin levels between patients with premature ejaculation and healthy subjects and the changes of leptin levels before and after treatment in patients with premature ejaculation. A major limitation is that a greater heterogeneity was identified through our analysis, however we did not find a definitive source of heterogeneity.
conclusionThere was a statistically significant relationship between serum leptin levels and patients with PE. In addition, serum leptin levels in patients with PE decreased significantly after 8 weeks of treatment with SSRIs. Liu G, Zhang Y, Zhang W, et al. Novel Marker for Premature Ejaculation: Serum Leptin Level. Sex Med 2022;10:100509.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.